Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of capmatinib + spartalizumab versus docetaxel in previously treated advanced non-small cell lung cancer
MOH_2019-02-03_005935Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing capmatinib + spartalizumab with docetaxel (2 arms). Primary endpoints: Safety and tolerability and Overall survival. Started Jan 2019; status: completed.
02
Drugs
capmatinibspartalizumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2019-02-03_005935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-03_005935.